Deal Announcements

Boston Scientific Acquires EndoTex For Undisclosed Sum

Thursday, January 04, 2007 7:30:00 AM PDT | VentureDeal Staff

NATICK, MA  --  Boston Scientific Corporation (NYSE: BSX) announced that it had acquired EndoTex Interventional Systems, following the FDA approval of EndoTex' NexStent (R) Carotid Stent System that was studied in a trial with Boston Scientifics FilterWire Embolic Protection System.

The NexStent system is a "laser-cut, nitinol stent with rolled sheet design that enables one stent size to adapt to multiple diameters in tapered or non-tapered vessel systems."

Terms of the transaction were not disclosed.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1